Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data.


Journal

Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 07 03 2021
accepted: 18 04 2021
pubmed: 18 5 2021
medline: 27 1 2022
entrez: 17 5 2021
Statut: ppublish

Résumé

To explore subretinal fluid (SRF) morphology in chronic central serous chorioretinopathy (cCSC) after one session of either high-density subthreshold micropulse laser (HSML) treatment or half-dose photodynamic therapy (PDT). We retrospectively obtained optical coherence tomography (OCT) scans from a subset of patients from a randomized controlled trial on treatment-naïve eyes with cCSC allocated to either HSML treatment or half-dose PDT. OCT scans were evaluated prior to treatment and 6-8 weeks post-treatment, where we measured maximum SRF height and width, calculated the maximum height-to-maximum width-ratio (maxHWR) and calculated the total SRF volume. Forty-one eyes of 39 cCSC patients were included. SRF morphology ranged from flat to dome-shaped, quantified as maxHWR ranging between 0.02 and 0.12. SRF volume was median 0.373 μl (range: 0.010-4.425 μl) and did not correlate to maxHWR (rho = -0.004, p = 0.982). Half-dose PDT was superior to HSML treatment in complete SRF resolution (RR = 3.28, p = 0.003) and in morphological changes of SRF (Δ SRF morphology changed after both HSML treatment and half-dose PDT in cCSC, with SRF disappearing in most PDT-treated patients, whereas SRF volume increased in a sizeable proportion of HSML-treated patients. Baseline SRF characteristics measured in this study were unable to predict outcomes after either HSML treatment or half-dose PDT.

Identifiants

pubmed: 33998168
doi: 10.1111/aos.14901
pmc: PMC9292654
doi:

Substances chimiques

Photosensitizing Agents 0
Verteporfin 0X9PA28K43

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

89-95

Subventions

Organisme : Stichting Blinden-Penning
Organisme : Stichting tot Verbetering van het Lot der Blinden
Organisme : Stichting Leids Oogheelkundig Ondersteuningsfonds
Organisme : Algemene Nederlandse Vereniging ter voorkoming van Blindheid
Organisme : Rotterdamse Stichting Blindenbelangen
Organisme : Stichting Ooglijders
Organisme : Stichting Blindenhulp
Organisme : Retina Nederland Onderzoek Fonds
Organisme : Landelijke Stichting voor Blinden en Slechtzienden
Organisme : the Netherlands Organisation for Scientific Research
Organisme : Mathilde Grant
Organisme : Macula Fonds

Informations de copyright

© 2021 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.

Références

Mol Genet Genomic Med. 2019 Apr;7(4):e00576
pubmed: 30724488
Prog Retin Eye Res. 2015 Sep;48:82-118
pubmed: 26026923
Lancet. 2020 Jan 25;395(10220):294-303
pubmed: 31982075
Graefes Arch Clin Exp Ophthalmol. 2019 Jul;257(7):1419-1425
pubmed: 31123815
Am J Ophthalmol. 2020 Apr;212:187-188
pubmed: 32007226
Eye (Lond). 2019 Jan;33(1):14-33
pubmed: 29995841
Ophthalmology. 2018 Oct;125(10):1547-1555
pubmed: 29776672
Retina. 2019 Feb;39(2):398-407
pubmed: 29190234
Clin Ophthalmol. 2016 Dec 20;11:39-46
pubmed: 28053499
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Trials. 2015 Sep 21;16:419
pubmed: 26390920
Prog Retin Eye Res. 2019 Nov;73:100770
pubmed: 31319157
Ophthalmology. 2008 Jan;115(1):169-73
pubmed: 18166410
Am J Ophthalmol. 2019 Sep;205:1-10
pubmed: 30951686
Eur J Ophthalmol. 2016 Aug 4;26(5):442-8
pubmed: 27135093
JAMA Ophthalmol. 2017 May 1;135(5):446-451
pubmed: 28334414
Acta Ophthalmol. 2018 Sep;96(6):e747-e749
pubmed: 29338129
Retina. 2020 Sep;40(9):1734-1741
pubmed: 31815877

Auteurs

Yousif Subhi (Y)

Department of Ophthalmology, Rigshospitalet-Glostrup, Copenhagen, Denmark.
Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark.

Jakob Bjerager (J)

Department of Ophthalmology, Rigshospitalet-Glostrup, Copenhagen, Denmark.

Camiel J F Boon (CJF)

Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
Department of Ophthalmology, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands.

Elon H C van Dijk (EHC)

Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH